### Dr. SARTORI Cesium therapy cure for Cancer: page 2/3 http://www.mwt.net/~drbrewer/highpH.htm
Cesium Therapy in Cancer Patients
H. E. SARTORI, M.D., Life Science Universal Medical Center, Suite 306, 4501 Connecticut A venue, Washington, DC 20008
SARTORI. H. E. Cesium Therapy in Cancer Patients. PHARMACOL BIOCHEM BEHAV 21: Suppl. I: 11-13. 1984 – The effect of cesium therapy on various cancers is reported. A total of 50 patients were treated over a 3 year period with CsCl. The majority of the patients has been unresponsive to previous maximal modalities of cancer treatment and was considered terminal cases. The Cs-treatment consisted of CsCl in addition to some vitamins, minerals, chelating agents, and salts of selenium, potassium and magnesium. In addition, a special diet was instituted. There was an impressive 5 year recovery of various cancers, including, cancers of unknown primary, breast, colon, prostate, pancreas, lung, and liver, lymphoma, Ewing sarcoma of the pelvis, and adenocarcinoma of the gallbladder by the Cstherapy employed. There was a 26% and 24% death within the initial 2 weeks and 12 months of treatment, respectively. A consistent finding in these patients was the disappearance of pain within the initial 3 days of Cs-treatment.
The small number of autopsies made showed the absence of cancer cells in most cases and the clinical impression indicates a remarkably successful outcome of treatment.
Cancer – Cancer personality – Cesium – Diet – Humans – Minerals – Vitamins
CERTAIN foods contain biologically active compounds and/or ingredients, i.e., vitamins, inorganic salts, organic compounds, essential fatty acids, minerals, and chelating agents which may either precipitate or prevent cancer development. The relationship between dietary consumption and cancer development is not clear and further investigation continues . Noteworthy is the report  on the presence of high levels of cesium (Cs) and rubidium (Rb) in food along with availability of various supportive compounds such as vitamins A and C along with zinc and selenium in diet of populations residing in areas with low incidence of cancer, e.g., the Hopi Indian territory in Arizona, the Hunza Land in Northern Pakistan, Vilcabamba, Ecuador, and the volcanic regions of Brazil. The diet of these populations is similar to the nutritive requirements for the high pH cancer therapy developed by Brewer  after a series of physical experiments with cancer cells.
In these tests the presence of Cs+ or Rb+ in the fluids adjacent to the tumor cells is believed to raise the pH of the cancer cells where cell mitosis will then cease resulting in reduction of life span of the cancer cell. The introduction of such alkaline pH by these alkali salts may also neutralize the acidic and toxic material within the cancer cell. This report combines the use of CsCl with various supportive agents, which have been hypothesized both to enhance the entry of Cs into the cancer cell and to stimulate the immune response, in the treatment of various cancers.
Treatment was performed on 50 patients during the last three years at Life Science Universal Medical Center Clinics in Rockville, Maryland and in Washington, D.C. All patients were terminal subjects with generalized metastatic disease. Forty-seven of the 50 patients studied had received maximal modalities of conventiona treatment, i.e., surgery, radiation, and various chemotherapies, before the metabolic Cs-treatment was initiated. Three patients were comatose and 14 of the patients were considered terminal due to previous treatment outcomes and cancer complications. The type of cancer of studied and the number of patients is detailed in Table I.
The Cs-treatment was given in conjunction with other supportive compounds. The patients were maintained on a cancer control diet. In addition, specific compounds and modalities were used to produce adequate circulation and oxygenation. According to individual cases, CsCl was given in daily dosages of 6 to 9 g, in three equally divided doses, in conjunction with vitamin A emulsion (100.000 to 300.000 I.U.), vitamin E (400 to 1000 I.U.), vitamin C (4 to 30 g), zinc (80 to 100 mg), selenium (600 to 1,200 mcg), and amygdalin (1,500 mg). Other supplementations were used according to the specific needs of the patient. The diet consisted mainly of brown rice, root and leafy vegetables, linolenic acid rich oils [linseed = flaxseed and walnut; soy (not for blood type O and B), wheat germ (not for Type Os)] and other supplemental foods.
To increase the efficiency of the treatment and to improve the circulation and oxygenation, the patients received the chelating agent (CaNa2) EDTA, dimethylsulfoxide (DMSO), and also a combination of vitamins, and K and Mg salts.
Table I summarizes the results of the Cs-treatment of 50 cancer patients studied for over 3 years. They had generalized metastatic disease, except for 3 patients. Initial death occurrences for the initial 2 weeks of treatment were in the same order and magnitude as these recorded for the 12 month period. The percent of survival of patients with breast, colon, prostate, and pancreas and cancers of unknown primary was 50%, while 3 out of 5 lung cancer patients, 2 out of 3 lymphoma patients, and one out 3 liver cancer patients treated in this series survived. An overall 50% recovery from cancer by the Cstherapy was determined in the 50 patients treated. Data from the autopsies made indicated the absence of tumors in patients dying within 14 days of the Cs-treatment.
One of the most striking effects of the treatment was the disappearance of pain in all patients within one to three days after initiation of the treatment. The disappearance of pain may be explained by changing the acidic pH that triggers the pain in the pain receptors to slightly alkaline where all pain sensations disappear. This does not only apply to cancer pain but also to arthritic and neuralgic pain that also consistently disappear after application of Cs, Rb, K, Mg, and Ca, in descending order of effectiveness. Pain relief from alkalinizing agents is primarily a function of a general shift of the body’s acid-base balance towards the alkaline that takes place preferentially in acidic areas and is a principle that was known in medicine since ancient times (see, e.g., Huáng Dì Nèi Jong, The Book of Internal Medicine of the Yellow Emperor).
TABLE I: THE EFFECT OF CsCl TREATMENT ON VARIOUS ADVANCED TYPES OF CANCER IN MAN
Morbidity Time Post Therapy
……….Number of Survivals
Breast** (10) .. 3*+ 2 5
Unknown Primary ….. (8) .. 2* 2 4
Colon .. (9) … 2 2 5
Prostate . (6) … 1* 2 3
Pancreas .. . (4) 1 1 2
Lung (5) … 1* .. 1 3
Liver (3) … 1 1 1
Lymphoma (3) … 1* - 2
Ewing Sarcoma Pelvis ……(1) ……. - . 1 -
Adenocancer of Gall bladder…………. (1) … 1 - … –
*An autopsy was performed on one patient of each group which did not indicate the presence of cancer
+ One case of breast cancer died to traumatic fracture of the neck.
These studies were performed under my direction, initiated in April 1981. Forty-eight patients were initially treated with CsCl between April 1981 and October 1982. They were subjected to various conventional cancer therapies such as surgery, radiation, and chemotherapy, and were considered terminal cases with general metastatic disease, except for 3 patients who were not previously treated. Three patients were comatose at the time of the Cs treatment.
Thirteen patients died within less than 2 weeks of treatment. Each patient showed a reduction in tumor mass by the Cs treatment. Of the breast cancer patients, the most impressive effect was seen in a 44 year old housewife who was comatose at the beginning of the Cs-treatment and was considered a terminal case with a life expectancy of at most of one week. The Cs-therapy, with the other ingredients used, was immediately instituted by the nasogastric route because there was no cooperation of the patient for regular oral administration possible. The daily CsCl dose amounted to 30 grams in three divided doses of 10 grams each. The patient regained consciousness within 24 hours after the initiation of the treatment and she was ready to leave her bed after five days on the therapy.
However, when attempting to get out of her bed, a fall that resulted in a fracture of cervical vertebra 2 caused her unfortunate demise within another 48 hours. The autopsy revealed that cancer metastasis had essentially “eaten away” parts of the neck, head, and trochanter of her hip bone causing this tragic accident.
The next most frequent cancer treated was of unknown primary.
Treatment of 8 cases showed a death rate of 2 within 14 days of treatment and an additional 2 deaths within 12 months while 4 of the patients are still living. In one case, an autopsy was made in a patient after one week of Cs treatment and showed a complete disappearance of the cancer. Thos patient’s death was attributed to the fulminant cardiotoxicity from her treatment with doxorubicin HCl (Adriamycin®) that had resulted in an intractable congestive heart failure. There were 7 cases of colon cancer patients who were treated with CsCl. Two of these patients died within 14 days. One of these two patients had previous massive chemotherapy and too little time was available to restore her bone marrow depression and dysmetabolic condition. The previously existing infiltration of the abdominal wall had disappeared in both patients. However, no consent was given for an autopsy.
In one lymphoma case the patient displayed a maximally extended spherical abdomen which was hard and he weighed approximately 112 kg (250 pounds). This massively enlarged abdomen progressively reduced in size with a loss of approximately 55 kg (121 lbs) of body weight after 3 months on the Cs therapy. Of this weight loss 30 kg (66 lbs) was attributed to ascites and 25 kg (55 lbs) to reduction of the tumor mass. The spleen which was originally maximally enlarged and reaching into the pelvis, was reduced to almost normal. The liver position was down to about the level of umbilicus and was reduced to normal size in 3 months. The patient is still living 3 years after his discharge. Unfortunately there was no follow-up on this patient and he is maintained on chemotherapy.
The results presented demonstrate the rate of efficacy of CsCl in cancer therapy. The total of 50 cancer cases shows an impressive 50% survival rate. This confirms the work of Messiha reported elsewhere in these proceedings showing that the higher the dose the more effective it seems. The autopsy obtained from the patient whose death was attributed to a traumatic fracture of the neck, indicates that the cancer has been initially further advanced resulting in bone destruction. However, the absence of cancer after the massive CsCl dose used in this case is demonstrable of the therapy. It appears that both dosage, i.e., as much as 30 grams/day, and route of drug administration, i.e., the nasogastric pathway, might have contributed to the patient’s rapid recovery.
It should be noted, however, that the oral CsCl dosage in humans should not exceed 20 to 40 grams/day to avoid side effects, notably nausea and diarrhea. The author’s personal experience with CsCl after an acute dose of 40 g CsCl indicates that extended nausea and paresthesias around the mouth are the major side effects. The latter is probably due to K depletion. The usual doses used in the clinic ranges from 2 to 3 g given by mouth 3 times daily.
At a latter time, at which time there is no indication of cancer presence, the CsCl dosage will be reduced to a preventative dose between 0.75 to 1.5 g a day. Less than 10 mg/kg or 0.6 g/60 kg of CsCl may enhance cancer growth.
The lymphoma case presented shows that CsCl efficiently reduced massive enlargements of spleen and liver as well as maximum ascites, causing an abdominal configuration of a tight, hard hemisphere to almost normalize after 3 months of therapy. This period of time was required to eliminate such a massive volume, resulting in the reduction of the body weight noted.
The clinical efficacy of CsCl high pH metabolic therapy is best demonstrated by a recent case of primary liver cancer (not included in the 50 cases reported in this study). The patient was a 39 year old female school teacher who was terminal. She was brought in the clinic on a stretcher on April 25, 1984 with a large liver tumor extending approximately 3 cm below the umbilical level with numerous large hard nodes ranging from 1.0 to over 5 cm (2/5 to > 2″) in diameter. The treatment was then immediately instituted. This consisted of administration of CsCl, o-carotene, vitamins A and C, Zn, Se, Mn, Cr and K salts by the oral route in addition to a concomitant massive I.V. doses of ascorbate, as well as K, Mg, Zn, Cu, Mn, and Cr salts, B-complex vitamins, folic acid, DMSO and heparin.
After five consecutive treatment regimens, EDTA was introduced to the therapy and the minerals present in the IV solution were discontinued. On May 10, 1984, the patient was discharged, returned home walking without assistance and displaying a pleasant smile on her face. The tumor- infiltrated liver had shrunk to 5 cm above the umbilicus or normal size and showed a smooth surface without any noticeable nodes. The determination of alphafetoprotein (AFP), a specific marker for liver cancers, and rare embryonic cancers and teratomas, decreased from an unusual high value of 39,000 units (120,000 og/L), compared to normal levels of
The mechanism of action of Cs in cancer has been little studied. That both Cs- and Rb- can specifically enter cancer cells and embryonic cells, but not normal adult cells, has been demonstrated by Brewer . The cancer cells contain high amounts of hydrogen ions rendering them acidic and they also contain higher Na+ levels than found in normal cells. If Cs- or Rb- enter the cancer cells, their pH increases from as low as 5.5 to over pH 7.0. At a pH of 7.6 the cancer cell division will stop, and at a pH of 8.0 to 8.5 the life span of cancer cells is considerably shortened (to only hours). In one case, the author has observed the shrinkage of metastases of breast cancer one hour after Cs-treatment. Two days later wrinkles of the skin appeared where the tumor had been present.
In another case of a colon cancer with massive metastasis, the massive infiltration of the abdominal wall, the liver and of other tissues seemed to have been reduced within 24 hours and was continuing rapidly until the demise of the patient on the 14th day of the Cs-treatment.
The uric acid levels measured at the onset of treatment were approximately 3.5 mg/dL (normal: 2.0 to 8.0 mg/dL) which was increased to over 20 mg/dL suggesting massive breakdown of DNA, specifically, the purine nucleotides adenosine and guanosine which are catabolized to uric acid. Therefore, destruction of nuclear acids, as reflected by a significant rise in serum uric acid, may be used as predictive measurements for treatment outcome. The failure of serum uric acid elevation may be indicative of lack of destruction of cancer cells. This has proven to be a very consistent finding in our clinic.
There are certain factors which may enhance the Cs therapy. The Cs+ penetration into the cancer cell can be increased by the following three methods: The first approach resides in broadening the electron donor capacity of the cancer cell membrane by the application of cyanide (CN-), an electron donor radical found in nitriles (amygdalin, Laetrile® or mandelonitrile, prunasin, ficin, or cassivin), by selenium and zinc ions, which are electron donor radicals, or by the use of DMSO. The second approach enhances the potential gradient across the cancer cell membrane by the utilization of weak acids like ascorbic acid (Vitamin C) and retinoic acid (Vitamin A). The third method attempts to improve the circulation to the tumor and facilitate the destruction of cross linkages in the mucoid and fibrinous substances around the cancer cell. This can be achieved by chelation therapy. i.e., the use of EDTA, preferably CaNa2-EDTA directly I.V., as has been shown by Blumer
(1), who reported on the reduction of cancer incidence by 90 % by chelating patients (an average of 15 chelations in 8 years). This approach also reduced cardiovascular disease by 50%. Other chelating agents can be also used. Moreover, the use of beta-carotene will lead to decomposition of blocking mucoid proteins which is mediated by electrical charges. Heparin which also acts through electrical charges will inactivate the immune repelling and immune binding capacities of the blocking mucoid proteins. These approaches will hinder cancer growth and they are virtually atoxic.
It should be noted that certain behavioral characteristics, “the cancer personality” of the cancer patient, may interfere in any projected treatment modality. This has been reported by Lawrence LeShan  in his book entitled “You Can Fight for Your Life.” His studies suggested that cancer patients seeking treatment, e.g., chemotherapy, radiation or surgery are probably motivated by a covert desire for death. They fail to express statements such as, “rather than undergoing any of those treatments, I would rather die in peace,” or “I would never undergo any of those treatments or let anyone of my family undergo them because the effectiveness is unproven, and the damage that is done with any of those treatments is higher than the effects”, and willingly and in spite of the obvious failure of the treatments and the sometimes horrendous side effects of chemotherapy opt for repeated courses of it until their eventual demise.
The most important psychological factors contributing to cancer are loss of a crucial relationship, both personal and professional, inability to express hostility or even show anger or aggression in self-defense, death of sibling or parent in early childhood causing tension, high degree of self-dislike or self-distrust, being programmed since early childhood that emotional relationships are dangerous and unsatisfying, being widowed, and, above all bleak, existential, passionless hopelessness and despair about ever achieving any meaning or validity in life. At the deepest emotional level, these people do not relate since they believe to be unworthy of love and summarize their lives as, “I’ve done nothing and been nothing”. [See also Note, below]. Thus, both, nutritional intake, as suggested herein, and lifestyle/psychological changes may contribute to an effective therapy of cancer (and other degenerative diseases).
The helpful assistance of Dr. Fathi S. Messiha in the preparation of this manuscript is gratefully acknowledged.
– 1. Blumer, W. and T. H. Reich. Leaded gasoline: A cause of cancer. Environ Intern 3: 465-471. 1980.
– 2. Brewer, K. A. Mechanism of carcinogenesis: Comments on therapy. J Int Acad Prev Med 5: 29–53. 1979.
– 3. Calloway, R. D., R. Giauque, and F. M. Costa. Superior mineral content of some American Indian Foods in comparison to Federal counterpart conated commodities. Ecol Food Nutr 3:203 -208, 1974.
– 4. Le Shan, L. You Can Fight For Your Life. Emotional Factors in the Treatment of Cancer. New York: M. Evans and Comp.,1977.
– 5. Special Report. Food and Cancer. Nutr Rev 24: 313-323. 1978.
Note: The connection between Blood Type and Cancer has been addressed in the endnote to the slightly edited “Nutrients and Cancer:
An Introduction to Cesium Therapy”, supra, in these proceedings, particularly, the proneness of Type As towards exhibiting the traits of “cancer personalities”.
# AUTHOR’S NOTE: Certain parts of the original manuscript that was submitted for publication were deleted by the editor of this journal as being too controversial or not sufficiently proven to warrant inclusion in this article. This slightly edited version restores the text of the original manuscript and on some places clarifies where all too terse language may have obscured the intended meaning.